type 1 diabetes, health status
Item
type 1 insulin-dependent diabetic patients in relatively good general condition
boolean
C0011854 (UMLS CUI [1])
C0018759 (UMLS CUI [2])
tobacco use
Item
non-smoker
boolean
C0543414 (UMLS CUI [1])
weight
Item
body weight < 80 kg
boolean
C0005910 (UMLS CUI [1])
c-peptide after glucagon
Item
c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after glucagon iv (1mg) (glycemia > 180 mg/dl)
boolean
C0202100 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C0017687 (UMLS CUI [1,3])
ebv antibody positive
Item
ebv antibody positive
boolean
C0241883 (UMLS CUI [1])
informed consent, compliance
Item
cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial.
boolean
C0021430 (UMLS CUI [1])
C1321605 (UMLS CUI [2])
thrombosis, pulmonary embolism
Item
history of thrombosis or pulmonary embolism
boolean
C0040053 (UMLS CUI [1])
C0034065 (UMLS CUI [2])
liver dysfunction
Item
abnormal liver function
boolean
C0086565 (UMLS CUI [1])
hla antibodies
Item
hla antibodies
boolean
C0024284 (UMLS CUI [1])